| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/19/2002 | US6358978 Substituted benzimidazoles |
| 03/19/2002 | US6358977 Therapy of neurodevelopmental disorder such as autistic spectrum disorders/autistic continuum disorders, pervasive developmental disorders, attention deficit hyperactivity disorder, etc., by administering piperidinemethanol compound |
| 03/19/2002 | US6358974 Used as as modulators of dopamine d.sub.3 receptors, in therapy as antipsychotic agents |
| 03/19/2002 | US6358972 5-HT1F agonists |
| 03/19/2002 | US6358966 Using 1-(4-(1-(4-fluorophenyl)-1h-indole-3-yl)-1-butyl spiro(isobenzofuran-1(3h,4-piperidine) |
| 03/19/2002 | US6358965 Use of benzoylalkyl-1,2,3,6-tetrahydropyridines |
| 03/19/2002 | US6358958 Arylpiperazines having activity at the serotonin 1A receptor |
| 03/19/2002 | US6358954 PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 03/19/2002 | US6358946 C-6 ring-substituted pyrido[1,2-a]benzimidazole derivatives useful in treating central nervous system disorders |
| 03/19/2002 | US6358945 Compounds useful as anti-inflammatory agents |
| 03/19/2002 | US6358944 Methods and compositions for treating generalized anxiety disorder |
| 03/19/2002 | US6358937 Administering phosphatidic acid and lipid to treat drug abuse, addiction, or withdrawal and/or alcoholism |
| 03/19/2002 | US6358923 Preventing and diagnosing blood, genetic, and nervous system disorders associated with decreased genetic expression |
| 03/19/2002 | US6358920 Nonapeptide anticarcinogenic and antimetastasis agents |
| 03/19/2002 | US6358732 Nucleotide sequences preferential polypeptides for use in the treatment of defects in central nervous system |
| 03/19/2002 | US6358706 Nucleotide sequences coding membrane protein; for use in treatment of epilepsy, schizophrenia, depression, sleep, stress, muscle, endocrine, respiratory, fertility, contraceptive, cardiovascular disorders and atherosclerosis |
| 03/19/2002 | US6358695 Determining compounds that activate or inhibit a g-protein receptor by exposing cells expressing the polypeptide on the surface with a test compound to allow binding and detect a signal in response to binding of agent to the polypeptide |
| 03/19/2002 | US6358527 Administering tablet comprising galanthamine hydrobromide, carrier comprising lactose monohydrate, microcrystalline cellulose and polymer disintegrant for therapy of dementia, mania or nicotine dependence |
| 03/19/2002 | CA2206804C Trisubstituted thioxanthines |
| 03/19/2002 | CA2193384C Use of gabapentin in the treatment of anxiety and panic |
| 03/19/2002 | CA2179521C 2,4-disulphophenyl butylnitrone, its salts and their use as pharmaceuti cal spintraps |
| 03/19/2002 | CA2128359C New benzospiroalkene derivatives, their preparation process and pharmaceutical compositions containing them |
| 03/19/2002 | CA2128287C Benzospiroalkene derivatives, their preparation process and pharmaceutical compositions containing them |
| 03/19/2002 | CA2079548C Carbamate derivatives of 4-amino-3- isoxazolidinones, 3-amino-1- hydroxypyrrolidin-2-ones and 1-amino-1- cyclopropanecarboxylic acid analogs, a process for their preparation and their use as medicaments |
| 03/19/2002 | CA2078885C Pharmaceutical compositions containing amethocaine |
| 03/19/2002 | CA2032797C Antithrombotic compounds |
| 03/18/2002 | CA2319928A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| 03/15/2002 | CA2357155A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/14/2002 | WO2002021141A2 Methods and compositions for diseases associated with amyloidosis |
| 03/14/2002 | WO2002021138A2 The m30 gene family and the utilization thereof |
| 03/14/2002 | WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | WO2002020807A1 L-methionine $g(g)-lyase with modified function |
| 03/14/2002 | WO2002020767A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020766A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020764A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020757A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020742A1 Use of ip3 kinases for preparing medicines for treating oxidative stress-related diseases |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | WO2002020722A2 Methods and compositions for in vitro targeting |
| 03/14/2002 | WO2002020615A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | WO2002020609A2 Interleukin-11 for the treatment of stroke and neuropathies |
| 03/14/2002 | WO2002020527A1 Soluble compounds for the inhibition of multidrug resistance and pharmaceutical compositions thereof |
| 03/14/2002 | WO2002020521A1 Use of indole derivatives for treating illnesses of the central nervous system |
| 03/14/2002 | WO2002020519A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | WO2002020511A1 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 03/14/2002 | WO2002020495A2 Inhibitors of glycogen synthase kinase 3 |
| 03/14/2002 | WO2002020492A1 Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor |
| 03/14/2002 | WO2002020485A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/14/2002 | WO2002020482A1 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl] methylpiperidine |
| 03/14/2002 | WO2002020480A1 Substituted fused pyrroleimines and pyrazoleimines |
| 03/14/2002 | WO2002020479A1 Substituted oxindole derivatives as tyrosine kinase inhibitors |
| 03/14/2002 | WO2002020465A2 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | WO2002020056A2 Methods and compositions for producing a neurosalutary effect in a subject |
| 03/14/2002 | WO2002020049A2 Eiav chimeric vaccine and diagnostic |
| 03/14/2002 | WO2002020047A2 Chlamydial peptides and their mimics in demyelinating disease |
| 03/14/2002 | WO2002020031A2 Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses |
| 03/14/2002 | WO2002020021A1 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| 03/14/2002 | WO2002020019A1 New use of quetiapine |
| 03/14/2002 | WO2002020016A1 AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA α7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY |
| 03/14/2002 | WO2002019967A2 Substituted hydrazine derivatives |
| 03/14/2002 | WO2002019961A2 Pharmaceutical compositions for headache, migraine, nausea and emesis |
| 03/14/2002 | WO2002019812A2 Mutant non-human mammal for expressing the alpha6 acetylcholine nicotinic receptor subunit and use for screening substances capable of interacting with said receptor |
| 03/14/2002 | WO2001093890A3 Botulinum toxin implant |
| 03/14/2002 | WO2001093827A3 Neurotoxin implant |
| 03/14/2002 | WO2001090189A3 G-protein coupled receptor org3. |
| 03/14/2002 | WO2001077147A3 New bromodomain protein |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001070668B1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 03/14/2002 | WO2001068612A3 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 03/14/2002 | WO2001066543A3 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 03/14/2002 | WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 03/14/2002 | WO2001064671A3 Haloimidazole derivatives and their use as muscarinic m3 and serotoninergic 5-ht4 receptors |
| 03/14/2002 | WO2001064668A3 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 03/14/2002 | WO2001062737A3 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 03/14/2002 | WO2001057085A3 G-protein coupled receptors |
| 03/14/2002 | WO2001055358A3 Phosphodiesterases |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001051512A3 Human and parasite orphan receptor proteins |
| 03/14/2002 | WO2001045715A3 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain |
| 03/14/2002 | WO2001045684A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001045683A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001045682A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001034113A3 Apparatus and method for preparing microparticles |
| 03/14/2002 | WO2001032161A3 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 03/14/2002 | WO2001023572A3 Polynucleotides and polypeptides encoded thereby |
| 03/14/2002 | WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 03/14/2002 | WO2000063441A3 Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease |
| 03/14/2002 | WO2000053742A9 Polynucleotides and proteins encoded thereby |
| 03/14/2002 | US20020032915 Detecting size defect in animal infants; obtain tissue biopsy, monitor expression of somatomedins in sample, amplified somatomedin concentration indicates potential size defect in animals |
| 03/14/2002 | US20020032234 First fatty acid compound that is a linoleic or linolenic compound and a second fatty acid that is a docosahexaenoic acid compound, an omega-3 or an omega-2 fatty acid or derivative |
| 03/14/2002 | US20020032229 Novel compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032217 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin |
| 03/14/2002 | US20020032207 2-Cyclohexyl quinazoline NMDA/NR2B antagonists |